Redemplo (plozasiran) is a targeted therapy approved for the treatment of familial chylomicronemia syndrome (FCS) in adults, in combination with a strict low-fat diet. FCS is a rare genetic lipid disorder in which the body cannot properly break down fats, leading to extremely high triglyceride levels and recurrent episodes of acute pancreatitis.

Redemplo is designed to reduce plasma triglycerides by lowering levels of apolipoprotein C-III (apoC-III)—a protein that inhibits the breakdown of triglyceride-rich lipoproteins. By silencing the gene that encodes apoC-III, Redemplo enhances the clearance of fat particles from the bloodstream, resulting in significant triglyceride reduction.